Sustained reduction of IL-23-related cytokines IL-17A and IL-22 in a phase 2 study of mirikizumab in the treatment of patients with moderately-to-severely active ulcerative colitis through week 52-MedSci.cn

Sustained reduction of IL-23-related cytokines IL-17A and IL-22 in a phase 2 study of mirikizumab in the treatment of patients with moderately-to-severely active ulcerative colitis through week 52

D'Haens, GR; Sands, BE; Kobayashi, T; Tuttle, JL; Schmitz, J; Higgs, R; Ho, S; Sissons, SE; Sandborn, WJ

JOURNAL OF CROHNS & COLITIS, 2020; 14 (): S525

科室
- - 订阅+
  - 更多科室
工具
服务